Literature DB >> 23784017

Survival for patients with single and multiple primary melanomas: the genes, environment, and melanoma study.

Anne Kricker1, Bruce K Armstrong, Chris Goumas, Nancy E Thomas, Lynn From, Klaus Busam, Peter A Kanetsky, Richard P Gallagher, Loraine D Marrett, Pamela A Groben, Stephen B Gruber, Hoda Anton-Culver, Stefano Rosso, Terence Dwyer, Marianne Berwick.   

Abstract

IMPORTANCE: Little is known about survival after a diagnosis of a second or higher-order (multiple) primary melanoma, and no study has explored survival in a population-based sample that included patients with single primary melanomas (SPMs) and multiple primary melanomas (MPMs) of any stage. Because people with a first primary melanoma are known to have an increased risk of being diagnosed with another, evidence for prognosis is needed.
OBJECTIVE: To determine whether survival after diagnosis was better in patients with MPMs than with SPMs, as suggested in a recent study. DESIGN Survival analysis with median follow-up of 7.6 (range, 0.4-10.6) years.
SETTING: The Genes, Environment, and Melanoma Study enrolled incident cases of melanoma from population-based cancer registries in Australia, Canada, Italy, and the United States. Multiple primary melanomas were ascertained during a longer period than SPM. PARTICIPANTS: Two thousand three hundred seventy-two patients with SPM and 1206 with MPM. EXPOSURE: Diagnosis with melanoma. MAIN OUTCOMES AND MEASURES: Melanoma-specific fatality hazard ratios (HR) and 95% confidence intervals associated with clinical and pathological characteristics of SPM, MPM, and both in Cox proportional hazards regression models.
RESULTS: Melanoma thickness was the main determinant of fatality (HR for >4 mm, 7.68 [95% CI, 4.46-13.23]); other independent predictors were ulceration, mitoses, and scalp location. After adjustment for these other predictors, we found little difference in fatality between MPM and SPM (HR for MPM relative to SPM, 1.24 [95% CI, 0.91-1.69; P = .18]). Thicker SPM, however, had higher fatality (HR for >4 mm, 13.56 [95% CI, 6.47-28.40]) than thicker MPM (2.93 [1.17-7.30]). CONCLUSIONS AND RELEVANCE: Although overall fatalities due to SPM and MPM were similar, relative fatality for thicker SPM was greater than that for thicker MPM. This finding may offer support for a difference in outcome between patients with SPM and MPM related to factors other than closer surveillance and earlier diagnosis. The better outcomes are worth further exploration.

Entities:  

Mesh:

Year:  2013        PMID: 23784017      PMCID: PMC3815536          DOI: 10.1001/jamadermatol.2013.4581

Source DB:  PubMed          Journal:  JAMA Dermatol        ISSN: 2168-6068            Impact factor:   10.282


  24 in total

1.  Number of primary melanomas is an independent predictor of survival in patients with metastatic melanoma.

Authors:  Rajmohan Murali; Philip T Brown; Richard F Kefford; Richard A Scolyer; John F Thompson; Michael B Atkins; Georgina V Long
Journal:  Cancer       Date:  2012-06-26       Impact factor: 6.860

2.  Single versus multiple primary melanomas: old questions and new answers.

Authors:  Charlotte Hwa; Leah S Price; Ilana Belitskaya-Levy; Michelle W Ma; Richard L Shapiro; Russell S Berman; Hideko Kamino; Farbod Darvishian; Iman Osman; Jennifer A Stein
Journal:  Cancer       Date:  2012-01-13       Impact factor: 6.860

3.  Tumor mitotic rate is a more powerful prognostic indicator than ulceration in patients with primary cutaneous melanoma: an analysis of 3661 patients from a single center.

Authors:  Manuela F Azzola; Helen M Shaw; John F Thompson; Seng-Jaw Soong; Richard A Scolyer; Geoffrey F Watson; Marjorie H Colman; Yuting Zhang
Journal:  Cancer       Date:  2003-03-15       Impact factor: 6.860

4.  Multiple primary melanoma - a review of 90 cases.

Authors:  A Scheibner; G W Milton; W H McCarthy; J J Norlund; L J Pearson
Journal:  Australas J Dermatol       Date:  1982-04       Impact factor: 2.875

5.  Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system.

Authors:  C M Balch; S J Soong; J E Gershenwald; J F Thompson; D S Reintgen; N Cascinelli; M Urist; K M McMasters; M I Ross; J M Kirkwood; M B Atkins; J A Thompson; D G Coit; D Byrd; R Desmond; Y Zhang; P Y Liu; G H Lyman; A Morabito
Journal:  J Clin Oncol       Date:  2001-08-15       Impact factor: 44.544

Review 6.  Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma.

Authors:  C M Balch; A C Buzaid; S J Soong; M B Atkins; N Cascinelli; D G Coit; I D Fleming; J E Gershenwald; A Houghton; J M Kirkwood; K M McMasters; M F Mihm; D L Morton; D S Reintgen; M I Ross; A Sober; J A Thompson; J F Thompson
Journal:  J Clin Oncol       Date:  2001-08-15       Impact factor: 44.544

7.  The prognostic importance of tumor mitotic rate confirmed in 1317 patients with primary cutaneous melanoma and long follow-up.

Authors:  Anne Brecht Francken; Helen M Shaw; John F Thompson; Seng-jaw Soong; Neil A Accortt; Manuela F Azzola; Richard A Scolyer; Gerald W Milton; William H McCarthy; Marjorie H Colman; Vincent J McGovern
Journal:  Ann Surg Oncol       Date:  2004-03-15       Impact factor: 5.344

Review 8.  An evidence-based staging system for cutaneous melanoma.

Authors:  Charles M Balch; Seng-Jaw Soong; Michael B Atkins; Antonio C Buzaid; Natale Cascinelli; Daniel G Coit; Irvin D Fleming; Jeffrey E Gershenwald; Alan Houghton; John M Kirkwood; Kelly M McMasters; Martin F Mihm; Donald L Morton; Douglas S Reintgen; Merrick I Ross; Arthur Sober; John A Thompson; John F Thompson
Journal:  CA Cancer J Clin       Date:  2004 May-Jun       Impact factor: 508.702

9.  Invasive cutaneous malignant melanoma in Sweden, 1990-1999. A prospective, population-based study of survival and prognostic factors.

Authors:  Christer Lindholm; Ronny Andersson; Monika Dufmats; Johan Hansson; Christian Ingvar; Torgil Möller; Helena Sjödin; Ulrika Stierner; Gunnar Wagenius
Journal:  Cancer       Date:  2004-11-01       Impact factor: 6.860

10.  Enhanced survival in patients with multiple primary melanoma.

Authors:  Anna Doubrovsky; Scott W Menzies
Journal:  Arch Dermatol       Date:  2003-08
View more
  11 in total

1.  Sun exposure and melanoma survival: a GEM study.

Authors:  Marianne Berwick; Anne S Reiner; Susan Paine; Bruce K Armstrong; Anne Kricker; Chris Goumas; Anne E Cust; Nancy E Thomas; Pamela A Groben; Lynn From; Klaus Busam; Irene Orlow; Loraine D Marrett; Richard P Gallagher; Stephen B Gruber; Hoda Anton-Culver; Stefano Rosso; Roberto Zanetti; Peter A Kanetsky; Terry Dwyer; Alison Venn; Julia Lee-Taylor; Colin B Begg
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2014-07-28       Impact factor: 4.254

2.  Separate Primary Melanomas of the Bulbar Conjunctiva and Eyelid Skin: Clinical Implications of Multiple Primary Melanomas.

Authors:  Frances A Jacinto; George H Fisher; Edgar M Espana; Ilya M Leyngold; Curtis E Margo
Journal:  Ocul Oncol Pathol       Date:  2016-04-21

3.  Second Primary Melanoma: Risk Factors, Histopathologic Features, Survival, and Implications for Follow-Up.

Authors:  Maris S Jones; Hitoe Torisu-Itakura; Devin C Flaherty; Hans F Schoellhammer; Jihey Lee; Myung-Shim Sim; Mark B Faries
Journal:  Am Surg       Date:  2016-10       Impact factor: 0.688

4.  Inherited variation at MC1R and ASIP and association with melanoma-specific survival.

Authors:  Nicholas J Taylor; Anne S Reiner; Colin B Begg; Anne E Cust; Klaus J Busam; Hoda Anton-Culver; Terence Dwyer; Lynn From; Richard P Gallagher; Stephen B Gruber; Stefano Rosso; Kirsten A White; Roberto Zanetti; Irene Orlow; Nancy E Thomas; Timothy R Rebbeck; Marianne Berwick; Peter A Kanetsky
Journal:  Int J Cancer       Date:  2014-11-26       Impact factor: 7.396

5.  Comparison of clinicopathologic features and survival of histopathologically amelanotic and pigmented melanomas: a population-based study.

Authors:  Nancy E Thomas; Anne Kricker; Weston T Waxweiler; Patrick M Dillon; Klaus J Busman; Lynn From; Pamela A Groben; Bruce K Armstrong; Hoda Anton-Culver; Stephen B Gruber; Loraine D Marrett; Richard P Gallagher; Roberto Zanetti; Stefano Rosso; Terence Dwyer; Alison Venn; Peter A Kanetsky; Irene Orlow; Susan Paine; David W Ollila; Anne S Reiner; Li Luo; Honglin Hao; Jill S Frank; Colin B Begg; Marianne Berwick
Journal:  JAMA Dermatol       Date:  2014-12       Impact factor: 10.282

6.  Relationship of Chromosome Arm 10q Variants to Occurrence of Multiple Primary Melanoma in the Population-Based Genes, Environment, and Melanoma (GEM) Study.

Authors:  Jonathan A Miles; Irene Orlow; Peter A Kanetsky; Li Luo; Anne E Cust; Bruce K Armstrong; Anne Kricker; Hoda Anton-Culver; Stephen B Gruber; Richard P Gallagher; Roberto Zanetti; Stefano Rosso; Lidia Sacchetto; Terence Dwyer; David C Gibbs; Klaus J Busam; Vikram Mavinkurve; David W Ollila; Colin B Begg; Marianne Berwick; Nancy E Thomas
Journal:  J Invest Dermatol       Date:  2018-12-17       Impact factor: 7.590

7.  Clinical characteristics and survival of lung cancer patients associated with multiple primary malignancies.

Authors:  Shan Shan; Jun She; Zhi-Qiang Xue; Chun-Xia Su; Shen-Xiang Ren; Feng-Ying Wu
Journal:  PLoS One       Date:  2017-09-28       Impact factor: 3.240

8.  Multiple Primary Cutaneous Melanomas in a Bulgarian Patient: The Possible Role of One Step Melanoma Surgery (OSMS) As the Most Adequate Treatment Approach!

Authors:  Georgi Tchernev; Ivanka Temelkova
Journal:  Open Access Maced J Med Sci       Date:  2018-11-21

9.  Outcomes and Risk Factors in Patients with Multiple Primary Melanomas.

Authors:  Adi Nosrati; Wesley Y Yu; Joseph McGuire; Ann Griffin; Juliana Rocha de Souza; Rasnik Singh; Eleni Linos; Mary Margaret Chren; Barbara Grimes; Nicholas P Jewell; Maria L Wei
Journal:  J Invest Dermatol       Date:  2018-07-19       Impact factor: 7.590

10.  Eleven Primary Melanomas, Colon Cancer, and Atypical Nevi in the Same Patient: A Case Report and Literature Review.

Authors:  Lea Juul Nielsen; Lisbet Rosenkrantz Hölmich
Journal:  Case Rep Dermatol Med       Date:  2016-02-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.